NO345131B1 - Kapselformulering av pirfenidon og farmasøytisk akseptable eksipienter - Google Patents
Kapselformulering av pirfenidon og farmasøytisk akseptable eksipienterInfo
- Publication number
- NO345131B1 NO345131B1 NO20080759A NO20080759A NO345131B1 NO 345131 B1 NO345131 B1 NO 345131B1 NO 20080759 A NO20080759 A NO 20080759A NO 20080759 A NO20080759 A NO 20080759A NO 345131 B1 NO345131 B1 NO 345131B1
- Authority
- NO
- Norway
- Prior art keywords
- pirfenidone
- pharmaceutically acceptable
- acceptable excipients
- capsule formulation
- capsule
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72025705P | 2005-09-22 | 2005-09-22 | |
PCT/US2006/037057 WO2007038315A2 (en) | 2005-09-22 | 2006-09-22 | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20080759L NO20080759L (no) | 2008-06-18 |
NO345131B1 true NO345131B1 (no) | 2020-10-12 |
Family
ID=37898745
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20080759A NO345131B1 (no) | 2005-09-22 | 2008-02-12 | Kapselformulering av pirfenidon og farmasøytisk akseptable eksipienter |
Country Status (29)
Country | Link |
---|---|
US (5) | US7988994B2 (no) |
EP (2) | EP2431025A1 (no) |
JP (3) | JP5837732B2 (no) |
KR (3) | KR101675651B1 (no) |
CN (3) | CN101267810A (no) |
AP (2) | AP2012006231A0 (no) |
AU (2) | AU2006295440B2 (no) |
BR (1) | BRPI0616324A2 (no) |
CA (2) | CA2762013C (no) |
CU (1) | CU20080043A7 (no) |
CY (1) | CY1115544T1 (no) |
DK (1) | DK1940364T4 (no) |
EA (1) | EA030093B1 (no) |
EC (1) | ECSP088394A (no) |
ES (1) | ES2496144T5 (no) |
GE (1) | GEP20115303B (no) |
HK (1) | HK1117762A1 (no) |
IL (2) | IL189273A (no) |
MA (1) | MA29875B1 (no) |
MX (1) | MX2008003882A (no) |
NO (1) | NO345131B1 (no) |
NZ (3) | NZ591443A (no) |
PL (1) | PL1940364T5 (no) |
PT (1) | PT1940364E (no) |
SI (1) | SI1940364T2 (no) |
TN (1) | TNSN08136A1 (no) |
UA (2) | UA99433C2 (no) |
WO (1) | WO2007038315A2 (no) |
ZA (1) | ZA200802237B (no) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002060446A1 (en) | 2001-01-29 | 2002-08-08 | Shionogi & Co., Ltd. | Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient |
MX2007014114A (es) | 2005-05-10 | 2008-03-14 | Intermune Inc | Derivados de piridona para modular el sistema de proteina cinasa activada por estres. |
NZ591443A (en) * | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
EP3053580B1 (en) | 2006-12-18 | 2021-06-30 | InterMune, Inc. | Method of providing pirfenidone therapy to a patient |
US20080242293A1 (en) * | 2007-04-02 | 2008-10-02 | Cequint, Inc. | System and method for providing caller id name display in wireless communications system |
WO2008147169A2 (es) * | 2007-05-29 | 2008-12-04 | Cell Therapy Technology, S.A. De C.V. | Microemolsion conteniendo pirfenidona |
US8383823B2 (en) | 2007-06-20 | 2013-02-26 | Auspex Pharmaceuticals | Substituted N-aryl pyridinones |
MX2007009796A (es) | 2007-08-14 | 2009-02-25 | Cell Therapy And Technology S | Gel conteniendo pirfenidona. |
ES2509143T3 (es) * | 2008-03-07 | 2014-10-17 | Solanan, Inc. | Tratamiento de una septicemia con 5-etil-1-fenil-2(1H)-piridona |
JP5627574B2 (ja) | 2008-06-03 | 2014-11-19 | インターミューン, インコーポレイテッド | 炎症性および線維性疾患を治療するための化合物および方法 |
US7635707B1 (en) * | 2008-11-10 | 2009-12-22 | Intermune, Inc. | Pirfenidone treatment for patients with atypical liver function |
AU2010206543A1 (en) * | 2009-01-26 | 2011-07-07 | Intermune, Inc. | Methods for treating acute myocardial infarctions and associated disorders |
US7816383B1 (en) | 2009-12-04 | 2010-10-19 | Intermune, Inc. | Methods of administering pirfenidone therapy |
CN101912395B (zh) * | 2010-08-12 | 2012-09-26 | 北京凯因科技股份有限公司 | 一种含吡非尼酮的药物组合物及其制备方法 |
US10105356B2 (en) | 2011-01-31 | 2018-10-23 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
ES2913095T3 (es) | 2011-01-31 | 2022-05-31 | Avalyn Pharma Inc | Compuestos de pirfenidona y análogos de piridona en aerosol y usos de los mismos |
AU2012225611B2 (en) | 2011-03-08 | 2016-09-15 | Auspex Pharmaceuticals, Inc. | Substituted N-Aryl pyridinones |
CN102670632A (zh) * | 2011-03-12 | 2012-09-19 | 赵海静 | 吡非尼酮在抑制皮肤瘢痕形成的医药用途 |
MX2011007675A (es) * | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas. |
US20130149383A1 (en) * | 2011-12-12 | 2013-06-13 | Cory Berkland | Sustained release particle formulations of guaifenesin |
MX346763B (es) | 2012-03-28 | 2017-03-31 | Cell Therapy And Tech S A De C V | Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné. |
MX356551B (es) | 2012-08-23 | 2018-06-04 | Grupo Medifarma S A De C V Star | Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné. |
CA2819967C (en) * | 2012-08-31 | 2016-03-22 | Intermune, Inc. | Use of pirfenidone concomitantly with ciprofloxacin |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
US9682071B2 (en) | 2013-03-15 | 2017-06-20 | Intermune, Inc. | Methods of improving microvascular integrity |
TN2016000207A1 (en) * | 2013-12-13 | 2017-10-06 | Novartis Ag | Pharmaceutical dosage forms. |
AU2015204558B2 (en) | 2014-01-10 | 2020-04-30 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
JP6525437B2 (ja) | 2014-04-02 | 2019-06-05 | インターミューン, インコーポレイテッド | 抗線維性ピリジノン |
JP6420459B2 (ja) * | 2014-04-11 | 2018-11-07 | ジェムバックス アンド カエル カンパニー,リミティド | 線維症抑制活性を有するペプチド及びこれを含む組成物 |
WO2016059815A1 (ja) * | 2014-10-15 | 2016-04-21 | 安良太 吾妻 | 癌化学予防薬 |
CA2937365C (en) * | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
TWI745396B (zh) * | 2016-07-12 | 2021-11-11 | 日商鹽野義製藥股份有限公司 | 吸入用醫藥組成物 |
KR102051559B1 (ko) * | 2016-12-09 | 2019-12-05 | 재단법인 아산사회복지재단 | 섬유증의 진단 또는 치료를 위한 스테아르산의 용도 |
KR20180100869A (ko) * | 2017-03-02 | 2018-09-12 | 영진약품 주식회사 | 피르페니돈의 입자크기 조절에 따른 타정성이 개선된 약제학적 조성물 및 이의 제조방법 |
WO2018195338A1 (en) * | 2017-04-20 | 2018-10-25 | Atyr Pharma, Inc. | Compositions and methods for treating lung inflammation |
MX366086B (es) | 2017-08-15 | 2019-06-27 | Cell Therapy And Tech S A De C V | Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel. |
EP3511001B1 (en) | 2018-01-12 | 2021-09-22 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pirfenidone-containing tablet and capsule formulation |
CN112469406B (zh) * | 2018-05-31 | 2024-05-17 | 财团法人峨山社会福祉财团 | 硬脂酸用于预防或治疗肺纤维化的用途 |
WO2020003107A1 (en) * | 2018-06-29 | 2020-01-02 | Zenvision Pharma Llp | Low dose oral pharmaceutical composition of pirfenidone or salt thereof |
WO2020115774A1 (en) | 2018-12-06 | 2020-06-11 | Cipla Limited | High drug load extended release formulations |
US20230000846A1 (en) | 2019-12-04 | 2023-01-05 | Idorsia Pharmaceuticals Ltd | Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases |
TW202142240A (zh) * | 2020-02-06 | 2021-11-16 | 日商力博美科股份有限公司 | 視網膜下高反射病灶或伴隨視網膜下高反射病灶之視網膜疾患的治療劑 |
EP4125890A1 (en) | 2020-04-01 | 2023-02-08 | Boehringer Ingelheim International GmbH | Use of biomarkers in the treatment of fibrotic conditions |
JP7490813B2 (ja) * | 2020-04-22 | 2024-05-27 | ユンジン ファーム.カンパニー、リミテッド | 安全性と安定性が改善されたピルフェニドンを含む腸溶性製剤およびその製造方法 |
KR20220107973A (ko) | 2021-01-25 | 2022-08-02 | 주식회사 나이벡 | 섬유화 예방 및 치료용 펩타이드 |
CN117224429B (zh) * | 2023-11-15 | 2024-02-06 | 南京天纵易康生物科技股份有限公司 | 一种含羟乙基纤维素作为崩解剂的烟酰胺/肽类固液分离护肤组合物及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3974281A (en) * | 1972-12-18 | 1976-08-10 | Affiliated Medical Research, Inc. | 5-Methyl-1-phenyl-2-(1H)-pyridone compositions and methods of use |
EP0383591A2 (en) * | 1989-02-15 | 1990-08-22 | Yamauchi, Shitotomo | Use of 5-methyl-1-phenyl-2-(1H)-pyridone in the prevention and treatment of fibrotic lesions |
EP1356816A1 (en) * | 2001-01-29 | 2003-10-29 | Shionogi & Co., Ltd. | Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4052509A (en) | 1972-12-18 | 1977-10-04 | Affiliated Medical Research, Inc. | Method for reducing serum uric acid levels |
US4042699A (en) | 1972-12-18 | 1977-08-16 | Affiliated Medical Research, Inc. | Method for reducing serum glucose levels |
US5518729A (en) | 1989-11-22 | 1996-05-21 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
US5310562A (en) | 1989-11-22 | 1994-05-10 | Margolin Solomon B | Composition and method for reparation and prevention of fibrotic lesions |
US5716632A (en) | 1989-11-22 | 1998-02-10 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
DE69431433T2 (de) * | 1993-05-07 | 2003-12-04 | Solomon B. Margolin | Zusammensetzungen und verfahren zur reparatur und vorbeugung fibrotischer verletzungen |
US5591766A (en) | 1993-12-03 | 1997-01-07 | Cheil Foods & Chemicals, Inc. | Solid oral formulations of pyridone carboxylic acids |
US6090822A (en) | 1995-03-03 | 2000-07-18 | Margolin; Solomon B. | Treatment of cytokine growth factor caused disorders |
US5962478A (en) | 1995-09-19 | 1999-10-05 | Margolin; Solomon B. | Inhibition of tumor necrosis factor α |
AU709178B2 (en) * | 1995-09-19 | 1999-08-26 | Intermune, Inc. | Inhibition of tumor necrosis factor alpha |
WO2001072285A1 (fr) * | 2000-03-27 | 2001-10-04 | Kyowa Hakko Kogyo Co., Ltd. | Granule facile a prendre |
WO2002087549A1 (fr) * | 2001-04-25 | 2002-11-07 | Taisho Pharmaceutical Co., Ltd. | Comprimes a liberation prolongee du type a unites multiples |
US7007089B2 (en) * | 2001-06-06 | 2006-02-28 | Akarnai Technologies, Inc. | Content delivery network map generation using passive measurement data |
US7512702B1 (en) * | 2002-03-19 | 2009-03-31 | Cisco Technology, Inc. | Method and apparatus providing highly scalable server load balancing |
US7139840B1 (en) * | 2002-06-14 | 2006-11-21 | Cisco Technology, Inc. | Methods and apparatus for providing multiple server address translation |
WO2004019758A2 (en) | 2002-08-27 | 2004-03-11 | Intermune, Inc. | Methods of treating idiopathic pulmonary fibrosis |
EP1551369A4 (en) * | 2002-08-28 | 2007-05-09 | Intermune Inc | COMBINATION THERAPY FOR THE TREATMENT OF FIBROTIC DISEASES |
US7159034B1 (en) * | 2003-03-03 | 2007-01-02 | Novell, Inc. | System broadcasting ARP request from a server using a different IP address to balance incoming traffic load from clients via different network interface cards |
BRPI0408805A (pt) * | 2003-03-31 | 2006-03-28 | Pliva Lachema As | composição farmacêutica contendo complexo de platina e método de fabricação da mesma |
US20050008691A1 (en) * | 2003-05-14 | 2005-01-13 | Arturo Siles Ortega | Bicalutamide compositions |
WO2004103296A2 (en) | 2003-05-16 | 2004-12-02 | Intermune, Inc. | Methods of treating idiopathic pulmonary fibrosis |
JP2007525188A (ja) | 2003-05-16 | 2007-09-06 | インターミューン インコーポレイテッド | 合成ケモカイン受容体リガンドおよびその使用方法 |
MXPA06000178A (es) * | 2003-07-01 | 2006-04-11 | Pharmacia & Upjohn Co Llc | Solidos modulados en la fase de difusion. |
US7407973B2 (en) | 2003-10-24 | 2008-08-05 | Intermune, Inc. | Use of pirfenidone in therapeutic regimens |
US7825133B2 (en) | 2003-11-14 | 2010-11-02 | Shanghai Genomics, Inc. | Derivatives of pyridone and the use of them |
SE0400235D0 (sv) * | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
US8642079B2 (en) * | 2004-02-23 | 2014-02-04 | Hormos Medical Corporation | Solid formulations of ospemifene |
US7584435B2 (en) * | 2004-03-03 | 2009-09-01 | Omniture, Inc. | Web usage overlays for third-party web plug-in content |
EP2305697A3 (en) | 2005-07-25 | 2011-07-27 | Intermune, Inc. | Macrocyclic inhibitors of Hepatitis C virus replication |
NZ591443A (en) * | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
-
2005
- 2005-09-22 NZ NZ591443A patent/NZ591443A/xx unknown
-
2006
- 2006-09-22 CN CNA2006800348742A patent/CN101267810A/zh active Pending
- 2006-09-22 NZ NZ600129A patent/NZ600129A/en unknown
- 2006-09-22 EP EP11007850A patent/EP2431025A1/en not_active Withdrawn
- 2006-09-22 AP AP2012006231A patent/AP2012006231A0/xx unknown
- 2006-09-22 GE GEAP200610558A patent/GEP20115303B/en unknown
- 2006-09-22 US US12/067,712 patent/US7988994B2/en active Active
- 2006-09-22 SI SI200631819T patent/SI1940364T2/sl unknown
- 2006-09-22 BR BRPI0616324-6A patent/BRPI0616324A2/pt not_active Application Discontinuation
- 2006-09-22 CN CN2013103433683A patent/CN103393607A/zh active Pending
- 2006-09-22 AP AP2008004390A patent/AP2655A/xx active
- 2006-09-22 ZA ZA200802237A patent/ZA200802237B/xx unknown
- 2006-09-22 ES ES06815221T patent/ES2496144T5/es active Active
- 2006-09-22 MX MX2008003882A patent/MX2008003882A/es active IP Right Grant
- 2006-09-22 DK DK06815221.4T patent/DK1940364T4/da active
- 2006-09-22 CA CA2762013A patent/CA2762013C/en active Active
- 2006-09-22 EP EP06815221.4A patent/EP1940364B2/en active Active
- 2006-09-22 NZ NZ565957A patent/NZ565957A/en unknown
- 2006-09-22 AU AU2006295440A patent/AU2006295440B2/en not_active Revoked
- 2006-09-22 KR KR1020147004496A patent/KR101675651B1/ko active IP Right Grant
- 2006-09-22 WO PCT/US2006/037057 patent/WO2007038315A2/en active Application Filing
- 2006-09-22 PL PL06815221.4T patent/PL1940364T5/pl unknown
- 2006-09-22 EA EA200800881A patent/EA030093B1/ru active Protection Beyond IP Right Term
- 2006-09-22 UA UAA200805048A patent/UA99433C2/ru unknown
- 2006-09-22 PT PT68152214T patent/PT1940364E/pt unknown
- 2006-09-22 CN CN201410057564.9A patent/CN103735530A/zh active Pending
- 2006-09-22 JP JP2008532431A patent/JP5837732B2/ja active Active
- 2006-09-22 CU CU20080043A patent/CU20080043A7/es unknown
- 2006-09-22 CA CA2620380A patent/CA2620380C/en active Active
- 2006-09-22 KR KR1020137022095A patent/KR101645069B1/ko active IP Right Grant
- 2006-09-22 UA UAA201203869A patent/UA115861C2/uk unknown
- 2006-09-22 KR KR1020087006806A patent/KR20080046673A/ko not_active Application Discontinuation
-
2008
- 2008-02-04 IL IL189273A patent/IL189273A/en active IP Right Grant
- 2008-02-12 NO NO20080759A patent/NO345131B1/no unknown
- 2008-03-19 TN TNP2008000136A patent/TNSN08136A1/en unknown
- 2008-04-17 MA MA30855A patent/MA29875B1/fr unknown
- 2008-04-22 EC EC2008008394A patent/ECSP088394A/es unknown
- 2008-09-26 HK HK08110737.9A patent/HK1117762A1/xx unknown
-
2009
- 2009-04-17 US US12/426,182 patent/US7767225B2/en active Active
-
2011
- 2011-04-05 AU AU2011201520A patent/AU2011201520B2/en not_active Revoked
- 2011-06-16 US US13/162,048 patent/US8383150B2/en active Active
-
2012
- 2012-08-17 JP JP2012180913A patent/JP5715101B2/ja active Active
-
2013
- 2013-02-25 US US13/776,079 patent/US8753679B2/en active Active
-
2014
- 2014-05-07 US US14/271,720 patent/US20140242159A1/en not_active Abandoned
- 2014-06-24 JP JP2014129551A patent/JP2014169341A/ja active Pending
- 2014-09-10 CY CY20141100731T patent/CY1115544T1/el unknown
-
2015
- 2015-07-09 IL IL239868A patent/IL239868A0/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3974281A (en) * | 1972-12-18 | 1976-08-10 | Affiliated Medical Research, Inc. | 5-Methyl-1-phenyl-2-(1H)-pyridone compositions and methods of use |
EP0383591A2 (en) * | 1989-02-15 | 1990-08-22 | Yamauchi, Shitotomo | Use of 5-methyl-1-phenyl-2-(1H)-pyridone in the prevention and treatment of fibrotic lesions |
EP1356816A1 (en) * | 2001-01-29 | 2003-10-29 | Shionogi & Co., Ltd. | Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO345131B1 (no) | Kapselformulering av pirfenidon og farmasøytisk akseptable eksipienter | |
LUC00127I1 (fr) | Dacomitinib et ses derives pharmaceutiquement accepatbles ( vizimpro ) | |
AP2008004447A0 (en) | Orally absorbed pharmaceutical formulation and method of administration | |
NO2018028I2 (no) | Kombinasjonen alogliptin og pioglitazon, hver eventuelt i form av et farmasøytisk akseptabelt salt derav | |
LU93189I2 (fr) | Ixekizumab et ses dérivés pharmaceutiquement acceptables (TALTZ) | |
DK1753406T4 (da) | Overtrukket tabletformulering og fremgangsmåde | |
IL184735A0 (en) | Pharmaceutical formulations and methods of use | |
DK1986679T3 (da) | Fremgangsmåde til forbedring af mikropartiklers farmaceutiske egenskaber omfattende diketopiperazin og et aktivt indholdsstof | |
DK1478339T3 (da) | Farmaceutiske formuleringer af antineoplastiske midler, specielt temozolomid, fremgangsmåder til fremstilling og anvendelse heraf | |
DK1673349T3 (da) | Benzimidazolderivater: fremstilling og farmaceutiske anvendelser | |
EP1765379A4 (en) | CO-CRISTAL PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | |
NO20055652D0 (no) | Laktatinneholdende farmasoytisk preparat og anvendelse av dette | |
IS2599B (is) | 3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólín og lyfjafræðilega viðurkenndar afleiður þess | |
DK2049525T3 (da) | N-laminoheteroaryl)-1H-indol-2-carboxamid-derivater, og fremstilling og terapeutisk anvendelse deraf | |
LU92326I2 (fr) | Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS) | |
IS8597A (is) | Samsetningar rísedrónats og aðferðir við notkun þess | |
HK1142823A1 (en) | Formulations for the oral administration of therapeutic agents and related methods | |
DK1773829T3 (da) | Aminotropanderivater, fremstilling og terapeutiske anvendelser heraf | |
DK1828137T3 (da) | 4-Cycloalkyl-substituerede tetrahydroquinolinderivater og deres anvendelse som medikamenter | |
NO20043333L (no) | Farmasoytiske parvastatinformuleringer og fremgangsmater for anvendelse av dem | |
HK1100352A1 (en) | Solid medicament of oral administration and preparation thereof | |
DK1940840T3 (da) | 6-heteroarylpyridoindolon-derivater, fremstilling deraf og terapeutisk anvendelse deraf | |
DK1819320T3 (da) | Oralt dispergerbar farmaceutisk sammensætning og fremgangsmåde til fremstilling heraf | |
NO20054370D0 (no) | Anvendelse av ATII-antagonist for behandling og forhindring av metabolsk syndrom | |
NO2017064I1 (no) | Kombinasjon av rilpivirine hydroklorid eller terapeutisk ekvivalent derav og emtricitabine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: INTERMUNE INC. C/O GENENTECH, US |